Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.37 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.36 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.36 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9434876 | 0.91 | ALOX15 (0.50) | ALOX15PIM1ALDH1A1TSHRDNM1 | |
| SCHEMBL27699518 | 0.91 | — | — | |
| SCHEMBL18871718 | 0.86 | ALOX15 (0.45) | ALOX15PIM1ALDH1A1TSHRDNM1 | |
| SCHEMBL5986738 | 0.86 | PIM1 (0.38) | PIM1ALDH1A1KDM1A | |
| SCHEMBL15401913 | 0.84 | ALOX15 (0.36) | ALOX15PIM1 | |
| SCHEMBL7029723 | 0.84 | ALOX15 (0.46) | ALOX15PIM1ALDH1A1TSHR | |
| SCHEMBL13760479 | 0.83 | ALOX15 (0.42) | ALOX15PIM1 | |
| SCHEMBL15334615 | 0.82 | ALDH1A1 (0.38) | ALOX15PIM1ALDH1A1TSHRKDM1A | |
| SCHEMBL9551161 | 0.82 | ALDH1A1 (0.38) | ALOX15PIM1ALDH1A1TSHRKDM1A | |
| SCHEMBL7649942 | 0.81 | HRH3 (0.52) | ALOX15ALDH1A1TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023003862-A1 | CXCR4 MODULATORS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2023-01-26 | — | — | WO | disclosed |
| WO-2021127278-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| US-20100068204-A1 | 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS | WYETH (US) | 2010-03-18 | — | — | US | disclosed |
| US-6479672-B1 | Diastereoselective preparation of Michael adducts | MERCK & CO., INC. | 2002-11-12 | — | — | US | disclosed |
| WO-2000061572-A1 | DIASTEREOSELECTIVE PREPARATION OF MICHAEL ADDUCTS | MERCK & CO., INC. (US) | 2000-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100068204-A1 | 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS | MTOR, RICTOR, PIK3CA | ALOX15 4482/4885PIM1 300/4885ALDH1A1 2884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.